Kodiak Sciences (KOD) Times Interest Earned (2017 - 2023)
Kodiak Sciences' (KOD) quarterly Times Interest Earned came in at -$0.13 in Q1 2026, up 99.59% YoY from -$0.06 in Q1 2025, and up 26.45% on a QoQ basis from -$0.18 in Q4 2025.
Powered by 
Analysis
Kodiak Sciences (KOD) Times Interest Earned (2017 - 2023) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Times Interest Earned data on file, last reported at -$0.13 in Q1 2026.
- Quarterly Times Interest Earned rose 99.59% year-over-year to -$0.13 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.51 (up 99.52% YoY) and the FY2025 annual result came in at -$0.71, up 5.53% from the prior year.
- Times Interest Earned improved to -$0.13 in Q1 2026, from -$0.18 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.13 in Q1 2026 to a low of -$18516.5 in Q4 2022.
- A 5-year average of -$1117.3 and a median of -$16.89 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned slumped 17227.6% — and 2023, when it surged 99.98%.
- Tracing KOD's Times Interest Earned over 5 years: stood at -$18516.5 in 2022, then surged by 99.98% to -$4.18 in 2023, then slumped by 1126.12% to -$51.31 in 2024, then surged by 99.66% to -$0.18 in 2025, then advanced by 26.45% to -$0.13 in 2026.
- The last three Times Interest Earned figures came in at -$0.13 (Q1 2026), -$0.18 (Q4 2025), and -$0.37 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Kodiak Sciences | 2.21 Bn | 2.21 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | -10,900.00 |
| Jun 30, 2023 | -21,208.00 |
| Mar 31, 2023 | -18,653.75 |
| Dec 31, 2022 | -18,516.50 |
| Sep 30, 2022 | -19,869.50 |
| Jun 30, 2022 | -18,413.60 |
| Mar 31, 2022 | -19,153.40 |
| Dec 31, 2021 | -3,101.63 |
| Sep 30, 2021 | -11,255.83 |
| Jun 30, 2021 | -11,181.80 |
| Mar 31, 2021 | -8,426.33 |
| Dec 31, 2020 | -7,807.00 |
| Sep 30, 2020 | -6,110.50 |
| Jun 30, 2020 | -4,463.17 |
| Mar 31, 2020 | -3,674.71 |
| Sep 30, 2019 | -6,366.00 |
| Jun 30, 2019 | -5,907.00 |
| Mar 31, 2019 | -2,115.00 |
| Dec 31, 2018 | -49.25 |
| Sep 30, 2018 | -3.22 |